CVD-REAL2: SGLT-2 inhibitors tied to better CV outcomes vs DPP-4 inhibitors
Patients with type 2 diabetes (T2D) who initiated SGLT2* inhibitors (SGLT2is) had better cardiovascular (CV) outcomes than those on DPP-4** inhibitors, shows the large, global, real-world study, CVD-REAL 2.